BioDuro and CTI Technology partner to push forward preclinical drug development

Published: 30-Apr-2026
Research & Development

The duo will combine their manufacturing experience and analytical capabilities to build an integrated platform spanning all the way from drug discovery to IND submission to accelerate the drug development path for clients

CRDMO BioDuro and preclinical research company CTI Technology have announced a new strategic partnership to fast-track preclinical drug development.

The pair will aim to establish an integrated platform spanning from drug discovery to investigational new drug (IND) submission.

Under this new partnership, BioDuro will provide integrated capabilities, including discovery chemistry, biology, drug metabolism and pharmacokinetics (DMPK) and pharmacology, as well as API and drug product development and manufacturing, together with IND filing support across global markets.

CTI Biotechnology will provide GLP toxicology studies and bioanalytical services to support successful IND submissions. 

By combining their complementary expertise and coordinating project execution, the two companies said they will deliver a "one-stop discovery and development solution" that will help clients streamline workflow, reduce communication and management complexity and more efficiently advance innovative therapies. 

Dr Armin Spura, CEO of BioDuro, said: "Successful IND submission depends on strong execution across every critical step of early development and GLP toxicology is one of the most important milestones in that journey."

By combining BioDuro's integrated discovery and development capabilities with CTI's proven expertise in GLP toxicology and bioanalytical services, we are strengthening our ability to help clients move innovative programmes forward with greater speed, confidence and efficiency.

"Our strategic collaboration with BioDuro will further enhance our combined service capabilities in preclinical development and provide clients worldwide with a more complete and efficient integrated solution," added Tony Liu, General Manager of CTI Biotechnology.

We look forward to working closely together to help accelerate our clients' R&D programmes and bring more innovative therapies to patients around the world.

  • Companies:
  • BioDuro-Sundia
See more

You may also like

Research & Development

BioDuro and Silicogenix join forces to lower complex therapeutic development barriers

Read more
The companies plan to facilitate the rapid and cost-effective testing and development of complex therapeutic molecules

Trending Articles

  1. Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    UK clinical trial reforms come into force in largest regulatory overhaul in 20 years The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
  3. AstraZeneca's tozorakimab succeeds in third pivotal Phase III COPD trial The positive results have shown that tozorakimab significantly reduced moderate-to-severe COPD exacerbations, adding to the earlier positive results from the OBERON and TITANIA trials and further supporting its potential as a first-in-class IL-33-targeting biologic
  4. Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development
  5. NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Research & Development

BioDuro and Silicogenix join forces to lower complex therapeutic development barriers

The companies plan to facilitate the rapid and cost-effective testing and development of complex therapeutic molecules
Manufacturing

BioDuro opens Chinese HPAPI synthesis laboratory

The Shanghai laboratory operates within OEB-5, producing highly potent compounds for use in early-stage drug conjugate development studies
Manufacturing

BioDuro-Sundia cuts the ribbon on Chinese kilogram-scale pilot production laboratory

The CRDMO can now scale-up the synthesis of drug candidates with complex APIs and advanced intermediates to preclinical/clinical phases
Research & Development

Scientists develop new technique to fight antimicrobial resistance

The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development

Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures

A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development

Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer

The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Subscribe now